C vs EBS
Citigroup Inc. (C) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
C currently screens at market cap $214.73B and trailing P/E 15.5. EBS currently screens at market cap $416.4M.
Not investment advice. Open the C and EBS stock pages for the full models.
Not investment advice.